A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
This study aim was to determine the safety and efficacy of R1507 in combination with letrozole in patients with advanced breast cancer. In the first part of the study a cohort of patients with advanced breast cancer received letrozole 2.5mg po daily in combination with R1507 16mg/kg every 3 weeks.
Breast Cancer
DRUG: RG1507|DRUG: Letrozole
Objective Tumor Response (Part 2), Up to 14 months
Pharmacokinetics (PK) Profile (Part 2), Up to 14 months|Progression-free Survival (Part 2), Up to 14 months|Number of Participants With Adverse Events (Part 2), Up to 14 months
This study aim was to determine the safety and efficacy of R1507 in combination with letrozole in patients with advanced breast cancer. In the first part of the study a cohort of patients with advanced breast cancer received letrozole 2.5mg po daily in combination with R1507 16mg/kg every 3 weeks.